linjc16/ctgov huggingface dataset:
Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients

Study Overview
=================
Brief Summary
-----------------
The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy & Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment. Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.

Official Title
-----------------
Stratification of Endometrial Carcinoma Patients Using Immunohistochemistry for Better Surgical Planning and Prognosis

Conditions
-----------------
Endometrial Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Tissue Biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 36 -72 years; Previously diagnosed with endometrial carcinoma; Histological Type of the tumor; Myometrial Invasion; lymph Node Invasion; Cervical Invasion; Biomarkers expression. Exclusion Criteria: Lack of tumor tissue in tissue block

Ages Eligible for Study
-----------------
Minimum Age: 36 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Study group<br> | Diagnostic Test: Tissue Biopsy<br>* The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM<br>|
| No Intervention: Excluded Patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| expression levels of p53/L1CAM/ER/PR | The Prognostic value of immunohistochemical detection of expression levels of p53/L1CAM/ER/PR in relation to ESMO-ESGO-ESTRO risk groups | 36 Months |
Predicting Factors for Mortality in Congenital Heart Disease Patients After Shunt Procedure in Developing Country.

Study Overview
=================
Brief Summary
-----------------
Blalock Taussig (BT) is a palliative procedure that preserves blood circulation to the lungs and alleviates cyanosis in patients with congenital heart diseases and reduced pulmonary blood flow. BT shunt remains a routinely performed procedure in developing countries before definitive surgery. However, evidence on predictors factors of mortality after this procedure is still scarce in Indonesia.

Official Title
-----------------
Predicting Factors for Mortality in Patients After the Modified Blalock-Taussig Shunt Procedure in Developing Country: a Retrospective Study

Conditions
-----------------
Cyanotic Congenital Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All CHD pediatric patients with a previous history of BT shunt procedure. Exclusion Criteria: Pediatric patients with incomplete medical records

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-Hospital Mortality | Death occured to patients during in hospital stay | November 2020 - January 2021 |
The Effect of Canal Dryness on the Quality of Obturation

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to evaluate root canal obturation quality. The questions to answer are what is the best protocol for canal dryness before obturation ? Is compaction necessary ? Volunteer participants will perform root canal treatment in teeth planned for extraction due to orthodontic reasons

Official Title
-----------------
The Effect of Different Canal Dryness Protocols on the Quality of Matched Single Cone Obturation: A Randomized Clinical Trial

Conditions
-----------------
Obturation

Intervention / Treatment
-----------------
* Procedure: Root canal obturation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy males and females (Category: American Society of Anesthesiologists class 1) aged 23-25 years presenting with sound maxillary premolars (non-carious and not previously restored) a radiographically visible root canal outline Exclusion Criteria: dental students of any level were not eligible to avoid including vulnerability factors. pregnant volunteers volunteers with complicating systemic disease (ASA 3-6) poor oral hygiene periodontal disease (probing depth >3 mm) related to the tooth

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Total dryness<br>matching paper points are used till they come out completely dry | Procedure: Root canal obturation<br>* Root canal dryness<br>|
| Active Comparator: Partial dryness<br>a single matching cone is inserted in the canal for 3 seconds only. | Procedure: Root canal obturation<br>* Root canal dryness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| obturation quality | percentage of voids within the filling by micro CT analysis | after 30 days |
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Study Overview
=================
Brief Summary
-----------------
The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Participants will receive the endocrine therapy before their surgery. The researchers will look at how changes in Ki67 expression compare between participants who are carriers of the BRCA2 mutation and participants who are noncarriers of the BRCA2 mutation.

Official Title
-----------------
Differential Changes in Ki67 Between Carriers and Noncarriers of BRCA2 Mutations With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Treated With Preoperative Endocrine Therapy

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: core needle biopsy
* Other: blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged ≥18 years with biopsy-proven stage I-III invasive breast cancer that is ER+/HER2- Scheduled to undergo upfront surgery Eligible for genetic testing in accordance with National Comprehensive Cancer Network guidelines Exclusion Criteria: History of breast cancer Receipt of ET for risk reduction in the previous 3 months Stage IV disease at presentation Scheduled to undergo neoadjuvant systemic chemotherapy Pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Breast Cancer<br>All study patients will receive standard ET for at least 2 weeks, which will be followed by standard of care surgical treatment. Surgical tumor tissue will be obtained at the time of surgery and will be assessed for Ki67; a portion of this specimen will be snap-frozen for future analysis. | Procedure: core needle biopsy<br>* Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied<br>Other: blood draw<br>* blood draw<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assess the change in Ki67 | The change in Ki67 expression on immunohistochemical staining from baseline to at least 2 weeks of ET will be assessed. | baseline to at least 2 weeks of endocrine therapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ki67 Expression, BRCA2 mutation, ER+/HER2-, endocrine therapy, 23-311
The Relationship Between Prolonged Hospitalization and Surgical Experience in Pediatric Tonsillectomy Cases.

Study Overview
=================
Brief Summary
-----------------
Guided by the expertise of a seasoned surgeon at the tertiary care hospital, the training program includes performing tonsillectomy starting from the 6th month. The clinical protocol at the hospital dictates a standard one-night hospital stay for all patients, but there is potential to extend the duration in specific cases. The study endeavors to explore the correlation between extended hospitalization, surgical proficiency, patient-specific factors, and postoperative complications in pediatric patients who underwent tonsillectomy and/or adenotonsillectomy at the clinic.

Official Title
-----------------
Pediatric Tonsillectomy: Surgical Experience And Prolonged Hospitalization

Conditions
-----------------
Sleep Apnea, Tonsillitis Recurrent

Intervention / Treatment
-----------------
* Other: PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients under 18 years of age having tonsillectomy surgery Patients whose records are available in the hospital archive Exclusion Criteria: Inadequate information in files

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| prolonged hospitalization after tonsillectomy<br>Prolonged hospitalization refers to prolonged discharge time and readmission. | Other: PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION<br>* we aim to compare hospitalization times of pediatric patients that operated by expert surgeon or young surgeon<br>|
| normal hospitalization time<br>normal hospitalization time for pediatric patients accepted as 1 night stay. | Other: PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION<br>* we aim to compare hospitalization times of pediatric patients that operated by expert surgeon or young surgeon<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of hospitalization lasting more than 24 hours |  | december'23- january'24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of postoperative complications | incidence of bleeding, respiratory problems | december'23- january'24 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tonsillectomy, Prolonged hospitalization
Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.

Detailed Description
-----------------
4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.

Official Title
-----------------
Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: Azvudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The COVID-19 positive patients Exclusion Criteria: patients treated with both azvudine and monotamivir; patients receiving other antiviral drugs such as nematavir/ritonavir; age &lt; 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Azvudine group<br>Azvudine group included COVID-19 patients treated with azvudine antiviral therapy; | Drug: Azvudine<br>* Received antiviral treatment with azvudine<br>|
| No antiviral group<br>No antiviral group included COVID-19 patients treated with no antiviral therapy; | |
| Monotamivir<br>Monotamivir group included COVID-19 patients treated with monotamivir antiviral therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality of COVID-19 patients | All-cause mortality of COVID-19 patients | Time from onset to death | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Azvudine, severity
Validation of UK Protocols to Exclude Brain Blood Flow During Normothermic Regional Perfusion (NRP)

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate both Abdominal Normothermic Regional Perfusion (A-NRP) and Thoracoabdominal-NRP (TA-NRP) techniques, proving that brain blood flow is not resumed during NRP. This will be assessed through the use of two modalities: CT angiogram of the brain and continuous Hb02 readings. The study group hypothesise that such assessment methods will provide evidence to indicate that brain blood flow is not present during NRP and promote trust in the use of such novel techniques in routine practice.

Official Title
-----------------
Validation of UK Protocols to Exclude Brain Blood Flow During Normothermic Regional Perfusion (NRP)

Conditions
-----------------
Cerebral Blood Flow

Intervention / Treatment
-----------------
* Procedure: CT angiogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DCD donors in Cambridge University Hospital Planned A-NRP Consent for study has been obtained Those who meet the appropriate criteria for DCD donation following WOLST ≥ 18 years of age ≤ 75 years of age Exclusion Criteria: DBD organ donors DCD organ donations outside of Cambridge University Hospital DCD donors without planned A-NRP DCD donors whose family have withheld consent for brain blood flow investigations. Patients who do not meet the appropriate criteria for DCD donation following WOLST Patients with injuries that will physically prevent use of the necessary assessment methods

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A-NRP<br> | Procedure: CT angiogram<br>* CT angiography of the brain 30 minutes from establishment of NRP<br>|
| TA-NRP<br> | Procedure: CT angiogram<br>* CT angiography of the brain 30 minutes from establishment of NRP<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CT angiogram | Brain blood flow | 30 minutes from establishment of NRP | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral oximetry | HbO2 measurements (O2Hbi (Delta oxygenated), HHbi (Delta deoxygenated), and cHbi (Delta total)) | Prior to withdrawal of life sustaining treatment to 30 minutes after establishment of NRP |
Outpatient Treatment of Severe and Enduring Anorexia Nervosa

Study Overview
=================
Brief Summary
-----------------
Approximately 20-30 % of individuals with the eating disorder anorexia nervosa develop an enduring form of the illness. In this study a new treatment for patients with severe and enduring anorexia nervosa was described. The treatment is flexible and aims at enhancing quality of life. The participants consisted of all referrals resulting in an assessment or treatment period at the unit between May 2017 and May 2022. The study was a registry study. Information regarding patient characteristics, treatment goals, and the course of treatment was gathered from medical records.

Official Title
-----------------
A Novel Outpatient Treatment for Patients With Severe and Enduring Anorexia Nervosa: Patient Characteristics, Treatment Goals, and Course of Treatment.

Conditions
-----------------
Anorexia

Intervention / Treatment
-----------------
* Behavioral: Outpatient treatment of severe and enduring anorexia nervosa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Age ≥ 18 years A referral resulting in an assessment or treatment period at the unit for patients with severe and enduring anorexia nervosa at the HUS Helsinki University Hospital between May 2017 and May 2022.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Outpatient treatment of severe and enduring anorexia nervosa|A novel outpatient treatment of severe and enduring anorexia nervosa, aiming at enhancing quality of life and minimizing harm|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| How the treatment goals were met | Whether or not the patients' individual treatment goals, defined at the beginning of treatment, had been met, partly met, or not met at the end of treatment. | At the end of treatment, an average of 15.4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anorexia nervosa, Severe and enduring anorexia nervosa, Treatment
Radiation Treatment of Lymph Node Recurrence From Prostate Cancer : is 11C-choline PET/CT Predictive of Survival Outcomes?

Study Overview
=================
Brief Summary
-----------------
The role of PET/CT with Choline in the restaging of prostatic disease is now universally recognized, and its use has become routine in numerous centers in Italy and abroad. The indication for the test is provided exclusively by an increase in PSA. It was interesting to understand whether these prognostic factors have an influence on the probability of detecting disease by PET with Choline to identify patients who have a greater probability of benefiting from the use of this method with the possibility of identifying the disease in earlier stages.

Official Title
-----------------
Radiation Treatment of Lymph Node Recurrence From Prostate Cancer : is 11C-choline PET/CT Predictive of Survival Outcomes?

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnostic accuracy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients operated with radical prostatectomy patients that present biochemical recurrence of the disease; Exclusion Criteria: patients <18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Diagnostic accuracy|The aim of the study is to evaluate whether the pathological stage of the disease, Gleason score, age at diagnosis, serum PSA value and PET parameters (SUV, MTV) are predictive factors of choline PET examination.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET/CT with Choline in the restaging of prostatic disease. | retrospective analysis of 68 patients with biochemical recurrence of prostase disease that performed PET/CT with choline for the restaging of the disease. | 1 year |